Exact Mass: 535.3005836
Exact Mass Matches: 535.3005836
Found 500 metabolites which its exact mass value is equals to given mass value 535.3005836
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Ergoloid
Ergoloid belongs to the class of organic compounds known as ergopeptines. These are ergoline derivatives that contain a tripeptide structure attached to the basic ergoline ring in the same location as the amide group of the lysergic acid derivatives. Ergoloid is considered to be a practically insoluble (in water) and relatively neutral molecule.
(4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine
(4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10S,11E)-10-hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-Hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine
3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine is an acylcarnitine. More specifically, it is an 3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine 3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-Hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine
(4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine is an acylcarnitine. More specifically, it is an (4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
valeryl 4-hydroxy valsartan
[(3R,5S,7R,8R)-7-{(1E,3E)-5-[(2S,3S,5R,6R)-5-{[(2Z,4S)-4-(acetyloxy)pent-2-enoyl]amino}-3,6-dimethyltetrahydro-2H-pyran-2-yl]-3-methylpenta-1,3-dien-1-yl}-8-hydroxy-1,6-dioxaspiro[2.5]oct-5-yl]acetic acid
Arg Phe Val Asp
Ile Phe Gln Glu
Lys Phe Asn Lys
Val Phe Asp Arg
Arg Val Phe Asp
Ala Phe Ile Trp
Ala Phe Leu Trp
Ala Phe Trp Ile
Ala Phe Trp Leu
Ala Ile Phe Trp
Ala Ile Trp Phe
Ala Leu Phe Trp
Ala Leu Trp Phe
Ala Trp Phe Ile
Ala Trp Phe Leu
Ala Trp Ile Phe
Ala Trp Leu Phe
Asp Phe Arg Val
Asp Phe Val Arg
Asp Arg Phe Val
Asp Arg Val Phe
Asp Val Phe Arg
Asp Val Arg Phe
Glu Phe Ile Lys
Glu Phe Ile Gln
Glu Phe Lys Ile
Glu Phe Lys Leu
Glu Phe Leu Lys
Glu Phe Leu Gln
Glu Phe Gln Ile
Glu Phe Gln Leu
Glu Ile Phe Lys
Glu Ile Phe Gln
Glu Ile Lys Phe
Glu Ile Gln Phe
Glu Lys Phe Ile
Glu Lys Phe Leu
Glu Lys Ile Phe
Glu Lys Leu Phe
Glu Lys Pro Tyr
Glu Lys Tyr Pro
Glu Leu Phe Lys
Glu Leu Phe Gln
Glu Leu Lys Phe
Glu Leu Gln Phe
Glu Pro Lys Tyr
Glu Pro Tyr Lys
Glu Gln Phe Ile
Glu Gln Phe Leu
Glu Gln Ile Phe
Glu Gln Leu Phe
Glu Tyr Lys Pro
Glu Tyr Pro Lys
Phe Ala Ile Trp
Phe Ala Leu Trp
Phe Ala Trp Ile
Phe Ala Trp Leu
Phe Asp Arg Val
Phe Asp Val Arg
Phe Glu Ile Lys
Phe Glu Ile Gln
Phe Glu Lys Ile
Phe Glu Lys Leu
Phe Glu Leu Lys
Phe Glu Leu Gln
Phe Glu Gln Ile
Phe Glu Gln Leu
Phe Ile Ala Trp
Phe Ile Glu Lys
Phe Ile Glu Gln
Phe Ile Lys Glu
Phe Ile Gln Glu
Phe Ile Arg Thr
Phe Ile Thr Arg
Phe Ile Trp Ala
Phe Lys Glu Ile
Phe Lys Glu Leu
Phe Lys Ile Glu
Phe Lys Lys Asn
Phe Lys Leu Glu
Phe Lys Asn Lys
Phe Lys Asn Gln
Phe Lys Gln Asn
Phe Leu Ala Trp
Phe Leu Glu Lys
Phe Leu Glu Gln
Phe Leu Lys Glu
Phe Leu Gln Glu
Phe Leu Arg Thr
Phe Leu Thr Arg
Phe Leu Trp Ala
Phe Asn Lys Lys
Phe Asn Lys Gln
Phe Asn Gln Lys
Phe Gln Glu Ile
Phe Gln Glu Leu
Phe Gln Ile Glu
Phe Gln Lys Asn
Phe Gln Leu Glu
Phe Gln Asn Lys
Phe Arg Asp Val
Phe Arg Ile Thr
Phe Arg Leu Thr
Phe Arg Thr Ile
Phe Arg Thr Leu
Phe Arg Val Asp
Phe Thr Ile Arg
Phe Thr Leu Arg
Phe Thr Arg Ile
Phe Thr Arg Leu
Phe Val Asp Arg
Phe Val Arg Asp
Phe Trp Ala Ile
Phe Trp Ala Leu
Phe Trp Ile Ala
Phe Trp Leu Ala
Ile Ala Phe Trp
Ile Ala Trp Phe
Ile Glu Phe Lys
Ile Glu Phe Gln
Ile Glu Lys Phe
Ile Glu Gln Phe
Ile Phe Ala Trp
Ile Phe Glu Lys
Ile Phe Glu Gln
Ile Phe Lys Glu
Ile Phe Arg Thr
Ile Phe Thr Arg
Ile Phe Trp Ala
Ile Ile Lys Tyr
Ile Ile Gln Tyr
Ile Ile Tyr Lys
Ile Ile Tyr Gln
Ile Lys Glu Phe
Ile Lys Phe Glu
Ile Lys Ile Tyr
Ile Lys Leu Tyr
Ile Lys Tyr Ile
Ile Lys Tyr Leu
Ile Leu Lys Tyr
Ile Leu Gln Tyr
Ile Leu Tyr Lys
Ile Leu Tyr Gln
Ile Gln Glu Phe
Ile Gln Phe Glu
Ile Gln Ile Tyr
Ile Gln Leu Tyr
Ile Gln Tyr Ile
Ile Gln Tyr Leu
Ile Arg Phe Thr
Ile Arg Thr Phe
Ile Thr Phe Arg
Ile Thr Arg Phe
Ile Trp Ala Phe
Ile Trp Phe Ala
Ile Tyr Ile Lys
Ile Tyr Ile Gln
Ile Tyr Lys Ile
Ile Tyr Lys Leu
Ile Tyr Leu Lys
Ile Tyr Leu Gln
Ile Tyr Gln Ile
Ile Tyr Gln Leu
Lys Glu Phe Ile
Lys Glu Phe Leu
Lys Glu Ile Phe
Lys Glu Leu Phe
Lys Glu Pro Tyr
Lys Glu Tyr Pro
Lys Phe Glu Ile
Lys Phe Glu Leu
Lys Phe Ile Glu
Lys Phe Lys Asn
Lys Phe Leu Glu
Lys Phe Asn Gln
Lys Phe Gln Asn
Lys Ile Glu Phe
Lys Ile Phe Glu
Lys Ile Ile Tyr
Lys Ile Leu Tyr
Lys Ile Tyr Ile
Lys Ile Tyr Leu
Lys Lys Phe Asn
Lys Lys Asn Phe
Lys Leu Glu Phe
Lys Leu Phe Glu
Lys Leu Ile Tyr
Lys Asn Phe Lys
Lys Asn Phe Gln
Lys Asn Lys Phe
Lys Asn Gln Phe
Lys Pro Glu Tyr
Lys Pro Tyr Glu
Lys Gln Phe Asn
Lys Gln Asn Phe
Lys Tyr Glu Pro
Lys Tyr Pro Glu
Leu Ala Phe Trp
Leu Ala Trp Phe
Leu Glu Phe Lys
Leu Glu Phe Gln
Leu Glu Lys Phe
Leu Glu Gln Phe
Leu Phe Ala Trp
Leu Phe Glu Lys
Leu Phe Glu Gln
Leu Phe Lys Glu
Leu Phe Gln Glu
Leu Phe Arg Thr
Leu Phe Thr Arg
Leu Phe Trp Ala
Leu Ile Gln Tyr
Leu Ile Tyr Gln
Leu Lys Glu Phe
Leu Lys Phe Glu
Leu Leu Gln Tyr
Leu Leu Tyr Gln
Leu Gln Glu Phe
Leu Gln Phe Glu
Leu Gln Ile Tyr
Leu Gln Leu Tyr
Leu Gln Tyr Ile
Leu Gln Tyr Leu
Leu Arg Phe Thr
Leu Arg Thr Phe
Leu Thr Phe Arg
Leu Thr Arg Phe
Leu Trp Ala Phe
Leu Trp Phe Ala
Leu Tyr Ile Gln
Leu Tyr Leu Gln
Leu Tyr Gln Ile
Leu Tyr Gln Leu
Asn Phe Lys Lys
Asn Phe Lys Gln
Asn Phe Gln Lys
Asn Lys Phe Lys
Asn Lys Phe Gln
Asn Lys Lys Phe
Asn Lys Gln Phe
Asn Gln Phe Lys
Asn Gln Lys Phe
Pro Glu Lys Tyr
Pro Glu Tyr Lys
Pro Lys Glu Tyr
Pro Lys Tyr Glu
Pro Arg Thr Tyr
Pro Arg Tyr Thr
Pro Thr Arg Tyr
Pro Thr Tyr Arg
Pro Tyr Glu Lys
Pro Tyr Lys Glu
Pro Tyr Arg Thr
Pro Tyr Thr Arg
Gln Glu Phe Ile
Gln Glu Phe Leu
Gln Glu Ile Phe
Gln Glu Leu Phe
Gln Phe Glu Ile
Gln Phe Glu Leu
Gln Phe Ile Glu
Gln Phe Lys Asn
Gln Phe Leu Glu
Gln Phe Asn Lys
Gln Ile Glu Phe
Gln Ile Phe Glu
Gln Ile Ile Tyr
Gln Ile Leu Tyr
Gln Ile Tyr Ile
Gln Ile Tyr Leu
Gln Lys Phe Asn
Gln Lys Asn Phe
Gln Leu Glu Phe
Gln Leu Phe Glu
Gln Leu Ile Tyr
Gln Leu Leu Tyr
Gln Leu Tyr Ile
Gln Leu Tyr Leu
Gln Asn Phe Lys
Gln Asn Lys Phe
Gln Tyr Ile Ile
Gln Tyr Ile Leu
Gln Tyr Leu Ile
Gln Tyr Leu Leu
Arg Asp Phe Val
Arg Asp Val Phe
Arg Phe Asp Val
Arg Phe Ile Thr
Arg Phe Leu Thr
Arg Phe Thr Ile
Arg Phe Thr Leu
Arg Ile Phe Thr
Arg Ile Thr Phe
Arg Leu Phe Thr
Arg Leu Thr Phe
Arg Pro Thr Tyr
Arg Pro Tyr Thr
Arg Thr Phe Ile
Arg Thr Phe Leu
Arg Thr Ile Phe
Arg Thr Leu Phe
Arg Thr Pro Tyr
Arg Thr Tyr Pro
Arg Val Asp Phe
Arg Val Val Tyr
Arg Val Tyr Val
Arg Tyr Pro Thr
Arg Tyr Thr Pro
Arg Tyr Val Val
Thr Phe Ile Arg
Thr Phe Leu Arg
Thr Phe Arg Ile
Thr Phe Arg Leu
Thr Ile Phe Arg
Thr Ile Arg Phe
Thr Leu Phe Arg
Thr Leu Arg Phe
Thr Pro Arg Tyr
Thr Pro Tyr Arg
Thr Arg Phe Ile
Thr Arg Phe Leu
Thr Arg Ile Phe
Thr Arg Leu Phe
Thr Arg Pro Tyr
Thr Arg Tyr Pro
Thr Tyr Pro Arg
Thr Tyr Arg Pro
Val Asp Phe Arg
Val Asp Arg Phe
Val Phe Arg Asp
Val Arg Asp Phe
Val Arg Phe Asp
Val Arg Val Tyr
Val Arg Tyr Val
Val Val Arg Tyr
Val Val Tyr Arg
Val Tyr Arg Val
Val Tyr Val Arg
Trp Ala Phe Ile
Trp Ala Phe Leu
Trp Ala Ile Phe
Trp Ala Leu Phe
Trp Phe Ala Ile
Trp Phe Ala Leu
Trp Phe Ile Ala
Trp Phe Leu Ala
Trp Ile Ala Phe
Trp Ile Phe Ala
Trp Leu Ala Phe
Trp Leu Phe Ala
Tyr Glu Lys Pro
Tyr Glu Pro Lys
Tyr Ile Ile Gln
Tyr Ile Leu Gln
Tyr Ile Gln Ile
Tyr Ile Gln Leu
Tyr Lys Glu Pro
Tyr Lys Pro Glu
Tyr Leu Ile Gln
Tyr Leu Leu Gln
Tyr Leu Gln Ile
Tyr Leu Gln Leu
Tyr Pro Glu Lys
Tyr Pro Lys Glu
Tyr Pro Arg Thr
Tyr Pro Thr Arg
Tyr Gln Ile Ile
Tyr Gln Ile Leu
Tyr Gln Leu Ile
Tyr Gln Leu Leu
Tyr Arg Pro Thr
Tyr Arg Thr Pro
Tyr Arg Val Val
Tyr Thr Pro Arg
Tyr Thr Arg Pro
Tyr Val Arg Val
Tyr Val Val Arg
PC(16:1/2:0)
4-[(9-cyclopentyl-6-oxo-5-propan-2-yl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide
C29H41N7O3 (535.3270716000001)
(2S,3S,6R)-3-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)-3-methylpentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2H-pyran-2-carboxylic acid
2-(1-hydroxypropan-2-yl)-3-oxo-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]heptanoic acid
(4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine
3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-Hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine
(4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-Hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine
2-methylpropyl N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
2-methylpropyl N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
2-methylpropyl N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
2-methylpropyl N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
2-methylpropyl N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(3-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
C30H37N3O6 (535.2682222000001)
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(3-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
C30H37N3O6 (535.2682222000001)
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-[2-(3-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
C30H37N3O6 (535.2682222000001)
N-[(4R,7S,8S)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
N-[(4R,7R,8S)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-[2-(3-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
C30H37N3O6 (535.2682222000001)
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-[2-(3-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
C30H37N3O6 (535.2682222000001)
N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-[2-(3-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
C30H37N3O6 (535.2682222000001)
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(3-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
C30H37N3O6 (535.2682222000001)
N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(3-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
C30H37N3O6 (535.2682222000001)
N-[(4S,7R,8S)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
N-[(4R,7R,8R)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
N-[(4S,7S,8R)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
N-[(4S,7R,8R)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
N-[(4R,7S,8R)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
2-methylpropyl N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
2-methylpropyl N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
[(1R)-2-[(2-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-(4-oxanyl)methanone
[(1S)-2-[(2-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-(4-oxanyl)methanone
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (Z)-tridec-9-enoate
2-amino-3-[hydroxy-[2-hydroxy-3-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropoxy]phosphoryl]oxypropanoic acid
(4E,8E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]dodeca-4,8-diene-1-sulfonic acid
C30H49NO5S (535.3331264000001)
(4E,8E,12E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxytetradeca-4,8,12-triene-1-sulfonic acid
C30H49NO5S (535.3331264000001)
(E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]dec-4-ene-1-sulfonic acid
C30H49NO5S (535.3331264000001)
(E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]dodec-4-ene-1-sulfonic acid
C30H49NO5S (535.3331264000001)
(4E,8E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxytetradeca-4,8-diene-1-sulfonic acid
C30H49NO5S (535.3331264000001)
[3-acetyloxy-2-[(Z)-hexadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (Z)-pentadec-9-enoate
[3-butanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-pentanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-octadec-9-enoate
[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-nonadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (Z)-tetradec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] (Z)-heptadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-hexadec-9-enoate
[2-[(Z)-pentadec-9-enoyl]oxy-3-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
1-[(9Z)-hexadecenoyl]-2-acetyl-sn-glycero-3-phosphocholine
A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at positions 1 and 2 are specified as (9Z)-hexadecenoyl and acetyl respectively.
MePC(17:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Tauroursodeoxycholate (dihydrate)
C26H49NO8S (535.3178714000001)
Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK[1][2].